S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:RYTM

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

$30.47
-0.53 (-1.71%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.14
$31.58
50-Day Range
$23.31
$34.24
52-Week Range
$3.04
$34.99
Volume
450,294 shs
Average Volume
623,211 shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.89

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
1.4% Upside
$30.89 Price Target
Short Interest
Bearish
16.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.69mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.56) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.17 out of 5 stars

Medical Sector

1008th out of 1,048 stocks

Pharmaceutical Preparations Industry

489th out of 513 stocks


RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
7 Best Rhythm Games On iOS And Android
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.89
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+1.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-69,610,000.00
Net Margins
-1,089.07%
Pretax Margin
-1,137.00%

Debt

Sales & Book Value

Annual Sales
$3.15 million
Book Value
$5.65 per share

Miscellaneous

Free Float
54,207,000
Market Cap
$1.72 billion
Optionable
Optionable
Beta
1.89

Key Executives

  • Dr. David P. Meeker M.D. (Age 69)
    Chairman, Pres & CEO
    Comp: $1.09M
  • Mr. Hunter C. Smith M.B.A. (Age 54)
    CFO & Treasurer
    Comp: $658.21k
  • Mr. Joseph Shulman (Age 48)
    Chief Technical Officer
    Comp: $555.66k
  • Mr. Yann Mazabraud (Age 50)
    Exec. VP & Head of International
    Comp: $693.62k
  • Ms. Jennifer L. Chien (Age 48)
    Exec. VP & Head of North America
    Comp: $597.46k
  • Mr. William T. Roberts (Age 44)
    Chief Accounting Officer
  • Mr. David Connolly
    Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty
    Sr. VP & Gen. Counsel
  • Ms. Sarah Ryan
    VP of Sales & Marketing
  • Ms. Pamela J. Cramer (Age 49)
    Chief HR Officer













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2023?

7 equities research analysts have issued twelve-month target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $40.00. On average, they expect the company's stock price to reach $30.89 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2023?

Rhythm Pharmaceuticals' stock was trading at $29.12 at the beginning of 2023. Since then, RYTM stock has increased by 4.6% and is now trading at $30.47.
View the best growth stocks for 2023 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $0.22. The business had revenue of $4.28 million for the quarter, compared to analyst estimates of $5.36 million. Rhythm Pharmaceuticals had a negative net margin of 1,089.07% and a negative trailing twelve-month return on equity of 72.83%.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.82%) and Hennion & Walsh Asset Management Inc. (0.11%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $30.47.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.72 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 140 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 1/27/2023 by MarketBeat.com Staff